Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Severe Pain Clear all
Completed Phase 2 Interventional Results available

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

NCT00975975
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
Interventions
Basiliximab
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 11, 2026, 6:52 AM EDT
Recruiting Phase 2 Interventional

Efgartigimod for the Treatment of Acute Optic Neuritis

NCT06453694
View directory record Official record
Conditions
Optic Neuritis
Interventions
Efgartigimod Alfa, Placebo
Drug
Lead sponsor
Anastasia Vishnevetsky, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain

NCT00627367
View directory record Official record
Conditions
Acute Pain
Interventions
Hydromorphone, Nonprotocolized
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

NCT04470544
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Camostat Mesilate, Standard of Care
Drug · Other
Lead sponsor
Alan Bryce
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cyclosporine For The Treatment Of COVID-19(+)

NCT04492891
View directory record Official record
Conditions
SARS (Disease)
Interventions
Cyclosporine, Standard of Care Treatment
Drug · Other
Lead sponsor
Bryan Burt, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 11, 2026, 6:52 AM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational

Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children

NCT04838834
View directory record Official record
Conditions
COVID-19, SARS-CoV-2, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Years to 27 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

NCT01280331
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antibody Detection of Vaccine-Induced Secretory Effects

NCT04895475
View directory record Official record
Conditions
Covid19, Humoral Acquired Immunodeficiency, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2 vaccine
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 11, 2026, 6:52 AM EDT
Not listed Phase 2Phase 3 Interventional

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

NCT04452565
View directory record Official record
Conditions
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone, Atazanavir and Dexamethasone
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination

NCT05977192
View directory record Official record
Conditions
Vaccination Hesitancy
Interventions
Standard MI, Intensive MI, MOTIVACC, Ecological momentary assessment (EMA) messages
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

NCT05142306
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
COVID-HIG
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 11, 2026, 6:52 AM EDT
Terminated Phase 3 Interventional

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Safety Evaluation of 3K3A-APC in Ischemic Stroke

NCT02222714
View directory record Official record
Conditions
Ischemic Stroke
Interventions
3K3A-APC, Placebo
Biological · Drug
Lead sponsor
ZZ Biotech, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 11, 2026, 6:52 AM EDT
Completed No phase listed Observational

Approaches and Decisions for Acute Pediatric TBI Trial

NCT04077411
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Observational
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 11, 2026, 6:52 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 11, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

Study of Pulmozyme to Treat Severe Asthma Episodes

NCT00169962
View directory record Official record
Conditions
Asthma
Interventions
rhDNAse (pulmozyme)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 11, 2026, 6:52 AM EDT